Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice
Interleukin 21 augments the hepatitis B virus-specific CD8+ T-cell response in vitro in patients coinfected with HIV-1
Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples
Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA
Fractures after antiretroviral initiation
Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM
Ribavirin and abacavir drug interaction in HIV–HCV coinfected patients
Estimating the cost-effectiveness of needle-syringe programs in Australia
Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis
Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons
The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting
Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy
Mucosal immunoglobulin A in HIV-exposed seronegative individuals
Human papillomavirus vaccination
HIV infection
Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection
Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial
Reply to ‘Declining adherence as a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial’
The pros and cons of urinary lipoarabinomannan testing
Reply to Boyles